Document Detail

Red blood cell transfusion risks in patients with end-stage renal disease.
MedLine Citation:
PMID:  22686519     Owner:  NLM     Status:  MEDLINE    
Prior to the introduction of recombinant human erythropoietin (EPO), red blood cell (RBC) transfusions were frequently required when iron and anabolic steroids failed to improve the clinical symptoms of anemia associated with hemoglobin (Hb) levels that were commonly less than 7 g/dl. After the approval of EPO in the United States in 1989, the Hb levels of patients on hemodialysis dramatically improved and the need for RBC transfusions decreased significantly. The need for RBC transfusion remains for patients who require an immediate increase in their RBC mass due to symptomatic anemia and is likely to increase due to changes in the management of anemia in dialysis patients resulting from clinical trials data, regulatory changes, and new reimbursement policies for EPO. The safety of the blood supply has greatly improved over the last few decades, and the risk of transfusion-transmitted diseases has now been dramatically reduced. Noninfectious complications of transfusion currently cause the majority of morbidity and mortality associated with transfusion in the United States. Transfusion also brings a risk of alloimmunization, a particular concern for dialysis patients waiting for kidney transplantation. Knowledge of the risks of RBC transfusions will help clinicians better assess the risks and benefits of transfusing patients with ESRD. This article reviews the modern day infectious and noninfectious risks of allogeneic RBC transfusions.
Yvette C Tanhehco; Jeffrey S Berns
Related Documents :
3776139 - Filterability of acd-stored red cells.
2628839 - Measurement of erythrocyte arginase activity and the effect of lead on the activity in ...
16699159 - Determining prevalence of bluetongue and epizootic hemorrhagic disease viruses in mule ...
25441549 - Evaluation of two glucose meters and interference corrections for screening neonatal hy...
627109 - Galactose-1-phosphate accumulation by a duarte-transferase deficiency double heterozygote.
17113119 - Optimization of ciguatoxin extraction method from blood for pacific ciguatoxin (p-ctx-1).
15537949 - Transport of phosphate through artificial macropores during film and pulse flow.
6795769 - Vascular abnormalities in diabetes and their treatment.
14498979 - Dynamics of simian immunodeficiency virus-specific cytotoxic t-cell responses in tissues.
Publication Detail:
Type:  Journal Article; Review     Date:  2012-06-11
Journal Detail:
Title:  Seminars in dialysis     Volume:  25     ISSN:  1525-139X     ISO Abbreviation:  Semin Dial     Publication Date:    2012 Sep-Oct
Date Detail:
Created Date:  2012-09-21     Completed Date:  2013-03-12     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  8911629     Medline TA:  Semin Dial     Country:  United States    
Other Details:
Languages:  eng     Pagination:  539-44     Citation Subset:  IM    
Copyright Information:
© 2012 Wiley Periodicals, Inc.
Division of Laboratory Medicine, Department of Pathology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / etiology*,  therapy*
Blood-Borne Pathogens
Erythrocyte Transfusion / adverse effects*
Erythropoietin / pharmacology
Hematinics / pharmacology
Hemoglobins / metabolism
Kidney Failure, Chronic / therapy*
Renal Dialysis* / adverse effects
Grant Support
Reg. No./Substance:
0/Hematinics; 0/Hemoglobins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence.
Next Document:  Focal cortical dysplasia type IIb in the rolandic cortex: Functional reorganization after early surg...